Update on opioids

Current Anaesthesia and Critical Care

Volumn 14, Issue 3, 2003, Pages 155-159

  Pleuvry, B J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Analgesia; Endorphins; Enkephalins; Morphine; Opioid; Receptors

Indexed keywords

BUPRENORPHINE; DELTA OPIATE RECEPTOR; DEXTROMETHORPHAN; ENDORPHIN; FENTANYL CITRATE; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NOCICEPTIN RECEPTOR; OPIATE; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; RECEPTOR SUBTYPE; TETRAPEPTIDE;

ANALGESIA; ARTICLE; CHRONIC PAIN; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; KNOCKOUT MOUSE; LOZENGE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0041919563     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-7112(03)00057-7     Document Type: Article

References (33)

1. Pleuvry A F, Pleuvry B J. Analgesia: Global Markets and Therapies. London: Informa Publishing Group, 2000.
2. Gaveriaux-Ruff C, Kieffer B L. Opioid receptors: gene structure and function. In: Stein C (ed.). Opioids in Pain Control. Cambridge: Cambridge University Press, 1999: 1-20.
3. Dhawan B N, Cesselin F, Raghubir R et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48(4): 567-592.
4. Darland T, Heinricher M M, Grandy D K. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 1998; 21(5): 215-221.
5. Calo' G, Rizzi A, Bigoni R, Guerrini R, Salvadori S, Regoli D. Pharmacological profile of nociceptin/orphanin FQ receptors. Clin Exp Pharmacol Physiol 2002; 29(3): 223-228.
6. Mei J, Pasternak G W. Sigma I receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 2002; 300(3): 1070-1074.
7. Maurice T, Martin-Fardon R, Romieu P, Matsumoto R R. Sigma(I) (sigma(I)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26(4): 499-527.
8. Crawford K W, Bowen W D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62(1): 313-322.
9. Tseng L F. Evidence for epsilon-opioid receptor-mediated beta-endorphin-induced analgesia. Trends Pharmacol Sci 2001; 22(12): 623-630.
10. Pan Y X, Xu J, Mahurter L, Bolan E, Xu M, Pasternak G W. Generation of the mu opioid receptor (MOR-I) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S A 2001; 98(24): 14084-14089.
11. Zadina J E, Hackler L, Ge L J, Kastin A J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386(6624): 499-502.
12. Kieffer B L, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66(5): 285-306.
13. Simonin F, Valverde O, Smadja C et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488 H and attenuates morphine withdrawal. EMBO J 1998; 17(4): 886-897.
14. Schuller A G, King M A, Zhang J et al. Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon I of MOR-I. Nat Neurosci 1999; 2(2): 151-156.
15. Ling G S, Spiegel K, Nishimura S L, Pasternak G W. Dissociation of morphine's analgesic and respiratory depressant actions. Eur J Pharmacol 1983; 86(3-4): 487-488.
16. Lotsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet 2001; 40(7): 485-499.
17. Stein C, Machelska H, Schafer M. Peripheral analgesic and anti-inflammatory effects of opioids. Z Rheumatol 2001; 60(6): 416-424.
18. Silbert S C, Beacham D W, McCleskey E W. Quantitative single-cell differences in mu-opioid receptor mRNA distinguish myelinated and unmyelinated nociceptors. J Neurosci 2003; 23(1): 34-42.
19. Machelska H, Cabot P J, Mousa S A, Zhang Q, Stein C. Pain control in inflammation governed by selectins. Nat Med 1998; 4(12): 1425-1428.
20. Kalso E, Smith L, McQuay H J, Andrew Moore R. No pain, no gain: clinical excellence and scientific rigour - lessons learned from IA morphine. Pain 2002; 98(3): 269-275.
21. DeHaven-Hudkins D L, Burgos L C, Cassel J A et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 1999; 289(1): 494-502.
22. Machelska H, Pfluger M, Weber W et al. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 1999; 290(1): 354-361.
23. Binder W, Machelska H, Mousa S et al. Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology 2001; 94(6): 1034-1044.
24. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100(3): 213-217.
25. Inturrisi C E. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18(4 Suppl): S3-13.
26. Williams J E, Louw G, Towlerton G. Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol Assess 2000; 4(32): iii-iv, 1-65.
27. Coluzzi P H, Schwartzberg L, Conroy J D et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91(1-2): 123-130.
28. Brunner G A, Balent B, Ellmerer M et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44(3): 305-308.
29. Dettmer K, Saunders B, Strang J. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ 2001; 322(7291): 895-896.
30. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence (Cochrane Review). In: The Cochrane Library, Issue I. Oxford: Update Software, 2003.
31. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence (Cochrane Review). In: The Cochrane Library, Issue I 2003. Oxford: Update Software.
32. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285(1): 45.
33. McQuay H J, Carroll D, Jadad A R et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994; 59(1): 127-133.